IDNT study - description and results

age between 30 and 70 years;type 2 diabetes mellitus; hypertension (systolic blood pressure of more than 135 mm Hg while sitting, a diastolic blood pressure of more than 85 mm Hg while sitting, or documented treatment with antihypertensive agents); proteinuria, with urinary protein excretion of at least 900 mg per 24 hours; serum creatinine between 1.0 and 3.0 mg per deciliter (88 and 265 ìmol per liter) in women and 1.2 and 3.0 mg per deciliter (106 and 265 ìmol per liter) in men.

Baseline characteristics

baseline BP	159/87 mmHg
Female (%)	32%
Age	58.6y
prior cardiovascular disease	29%

Results

Endpoint Studied treat.
n/N Control treat.
n/N Graph RR [95% CI]

All cause death

83 / 567
93 / 569
0,90 [0,68;1,18] 0 2 1.0

Endpoint	Events (%)		Relative Risk	95% CI	Endpoint definition in the trial	Ref
Relative risks
Endpoint	Studied treat.	Control treat.	Relative Risk	95% CI	Endpoint definition in the trial	Ref
All cause death	83 / 567 (14,6%)	93 / 569 (16,3%)	0,90	[0,68;1,18]
The primary endpoint (if exists) appears in blod characters
Reference(s) used for data extraction:

Endpoint	Events rate		Absolute risk reduction (ARR)
Absolute risk reduction
Endpoint	Studied treat.	Control treat.	Absolute risk reduction (ARR)
All cause death	14,64%	16,34%	-17,1‰

Reference(s)

Trials register #

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.. N Engl J Med 2001;345:851-60

Pubmed | Hubmed | Fulltext

IDNT study, 2001

Treatments

Patients

Method and design

Results

Reference(s)